QUADRA Trial Dosing

For Treatment of Advanced HRD+ Ovarian Cancer After Three or More Chemotherapies1

The approved starting dose of ZEJULA for treatment of advanced HRD+ ovarian cancer is 300 mg/day

ZEJULA Recommended Dose Modifications for Adverse Reactions1

Starting Dose

Dose modifications

For patients with moderate hepatic impairment, reduce the starting dosage of ZEJULA to 200 mg once daily. Monitor patients for hematologic toxicity and reduce the dose further, if needed.

Adverse Reactions in QUADRA Were Consistent With Other Clinical Findings in NOVA1

Adverse reactions reported in ≥10% of patients receiving ZEJULA in QUADRA

Adverse reactions of ZEJULA (niraparib) in QUADRA
Adverse reactions reported in >= 10% of patients in QUADRA

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Adverse reactions in QUADRA led to dose reduction or interruption, 73%1

Most frequently from:

  • Thrombocytopenia, 40%
  • Anemia, 21%
  • Neutropenia, 11%
  • Nausea, 13%
  • Vomiting, 11%
  • Fatigue, 9%
  • Abdominal Pain, 5%

Discontinuation, 21%

CBC, complete blood count; CTCAE, Common Terminology Criteria for Adverse Events, version 4.02; HRD+, homologous recombination deficiency positive.

Efficacy Data

View efficacy data for
all indications

Reference: 1. ZEJULA (niraparib). Prescribing Information. GlaxoSmithKline; 2021.